A chemogenomic approach to discovering target-selective drugs.
An approach is described for identifying scaffolds with predefined selectivity profiles directly from a high-quality high-throughput screening data set, and monitoring that selectivity profile throughout the drug discovery process. This approach results in reduced drug development timelines from "hit" to "lead" stage, and should reduce liabilities for a molecule advancing through the development process.
Amphora Discovery Corporation, 800 Capitola Drive, Durham, NC 27713, USA.
William P
WP
Janzen
C Nicholas
CN
Hodge
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D030562:Databases, Protein; D015195:Drug Design; D013329:Structure-Activity Relationship; D013678:Technology, Pharmaceutical